Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-117 (Omidenepag Isopropyl) Dosing Study in Glaucoma and Ocular Hypertension
NCT03858894Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omidenepag isopropyl in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Intraocular Pressure at 6 weeks. Started Jan 2019; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03858894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858894.